Efficacy and safety of the russian GLP-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus in real-world clinical practice (“QUEENPROMIS” study)
Authors:
- Antsiferov M.B. AntsiferovAAAntsiferov M.B. Antsiferov
- Koteshkova O.M. KoteshkovaKKKoteshkova O.M. Koteshkova
- Antsiferova D.M. AntsiferovaAAAntsiferova D.M. Antsiferova
- Romashkina L.P. RomashkinaRRRomashkina L.P. Romashkina
- 19 December 2025
- journal article
- Published by Bionika Media in Pharmateca
- Vol. 8_2025